spacer
The Healthcare Sales & Marketing Network celebrates 25 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  rhinosinusitis 

 HSMN NewsFeed - 2 Feb 2023
Tezspire(R) Approved for Self-Administration in the U.S. with a New Pre-Filled Pen
Biopharmaceuticals Drug Delivery FDA
 HSMN NewsFeed - 5 Jul 2022
Lyra Therapeutics Announces Appointment of Richard Nieman, MD, as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 13 May 2022
Medtronic completes acquisition of Intersect ENT
Devices Mergers & Acquisitions
 HSMN NewsFeed - 13 Apr 2022
Lyra Therapeutics Announces Closing of $100.5 Million Private Placement
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 7 Mar 2022
Lyra Therapeutics Appoints Jim Tobin to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 24 Jan 2022
Lyra Therapeutics Announces Initiation of LYR-210 Pivotal Phase 3 ENLIGHTEN Program in Surgically Naïve Chronic Rhinosinusitis Patients
Devices Drug Delivery
 HSMN NewsFeed - 20 Oct 2021
FDA Expands Approval of Dupixent(R) (dupilumab) to Include Children Aged 6 to 11 Years with Moderate-to-severe Asthma
Biopharmaceuticals FDA
 HSMN NewsFeed - 6 Aug 2021
Medtronic to Acquire Intersect ENT
Devices Mergers & Acquisitions
 HSMN NewsFeed - 1 Dec 2020
Novartis announces FDA approval of Xolair(R) (omalizumab) for adults with nasal polyps
Biopharmaceuticals FDA
 HSMN NewsFeed - 19 Jun 2020
Dupixent(R) (dupilumab) Approved in China for Adults with Moderate-to-Severe Atopic Dermatitis
Biopharmaceuticals Dermatology Regulatory
 HSMN NewsFeed - 6 Aug 2019
Dupixent(R) (dupilumab) Approved by European Commission for Adolescents with Moderate-to-Severe Atopic Dermatitis
Biopharmaceuticals Dermatology Regulatory
 HSMN NewsFeed - 7 May 2019
Dupixent(R) (dupilumab) Approved for Severe Asthma by European Commission
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 1 Mar 2019
CHMP Recommends Approval of Dupixent(R) (dupilumab) for Asthma Indication
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 22 Oct 2018
FDA Approves Asthma Indication for Dupixent(R) (dupilumab)
Biopharmaceuticals FDA
 HSMN NewsFeed - 30 Jan 2017
AmpliPhi Biosciences Appoints Dr. Igor P. Bilinsky as Senior Vice President and Chief Operating Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 6 Oct 2015
OptiNose Closes New Round of Financing
Devices Drug Delivery Venture Capital
 HSMN NewsFeed - 17 Feb 2014
New Study Affirms In-Office Multi-Sinus Balloon Dilation is an Effective, Well Tolerated Treatment Option for Chronic Sinusitis Sufferers
Devices
 HSMN NewsFeed - 19 Sep 2013
Published Study Demonstrates Benefits of Balloon Sinus Dilation versus Endoscopic Sinus Surgery for Sinusitis Patients
Devices Interventional
 HSMN NewsFeed - 25 Jul 2013
Study Shows Benefits of Balloon Sinus Dilation versus Traditional Sinus Surgery for Chronic Sinusitis
Devices
 HSMN NewsFeed - 28 Apr 2011
Entellus Medical(TM) Study Demonstrates XprESS(TM) Multi-Sinus Dilation Tool Safe and Effective in Treatment of Chronic Sinusitis
Devices
 HSMN NewsFeed - 25 Feb 2011
Medtronic Announces Purchase of Innovative Gel Technology for Potential Use in Functional Endoscopic Sinus Surgery (FESS)
Devices Surgery Acquisitions
 HSMN NewsFeed - 23 Feb 2011
Entellus Medical(TM) Receives FDA 510(k) Clearance for FinESS(TM) Endoscope
Devices FDA
 HSMN NewsFeed - 27 Sep 2010
Acclarent, Inc. Introduces Two New Innovations for Minimally-Invasive Sinus Surgery during AAO - Head and Neck Surgery Conference
Devices Surgery
 HSMN NewsFeed - 7 Apr 2010
Medtronic Launches New Frontal Handpiece for Its Hydrodebrider System
Devices
 HSMN NewsFeed - 4 May 2009
Acclarent, Inc. Granted Key Patent Covering Balloon Sinuplasty(TM) Technologies
Devices
 HSMN NewsFeed - 24 Sep 2008
New Studies Highlight Benefits of Coblation(R)-Assisted Procedures in Airway Fire Prevention and Endoscopic Sinus Surgery
Devices Surgery
 HSMN NewsFeed - 22 Sep 2008
Entellus Medical(R) Launches FinESS(TM) Sinus Treatment at American Academy of Otolaryngology (AAO) Annual Meeting
Devices
 HSMN NewsFeed - 17 Apr 2008
Accentia Announces that After Reviewing Unblinded Results, Independent DMC Recommends Presenting Data on BiovaxID(R) to FDA and Worldwide Regulatory Agencies in Order to Seek Marketing Approvals for Follicular Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 24 Mar 2008
Accentia Biopharmaceuticals Announces Results on Primary Endpoint in Clinical Study of SinuNase Lavage
Biopharmaceuticals
 HSMN NewsFeed - 29 Nov 2007
New Medical Device and Irrigation Solution Exhibits Promising Results in the Removal of Bacterial Colonization in Chronic Sinus Infections
Devices
 HSMN NewsFeed - 26 Nov 2007
Carbylan Announces $20 Million Series B Financing
Devices Venture Capital
 HSMN NewsFeed - 16 Oct 2007
Biovest Announces Strategy for Seeking Early Approval of Its Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Oct 2007
Accentia Announces Investigational New Drug Application for Revimmune Usage in a Pivotal Phase 3 Study of Refractory Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 8 Oct 2007
Accentia Biopharmaceuticals Announces Completion of Enrollment in Fast-Tracked Pivotal Phase 3 Clinical Trial of SinuNase for Chronic Sinusitis
Biopharmaceuticals
 HSMN NewsFeed - 15 Aug 2007
Accentia Biopharmaceuticals Updates Interim Analysis of Blinded Clinical Results in the Fast-Tracked Pivotal Phase 3 Trial of SinuNase for the Treatment of Refractory Chronic Sinusitis
Biopharmaceuticals
 HSMN NewsFeed - 31 Jul 2007
Accentia Biopharmaceuticals Files Pre-Investigational New Drug (IND) Application with FDA for Pivotal Phase 3 Clinical Trial of Revimmune for Refractory Multiple Sclerosis
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 5 Jun 2007
Biovest to File for Accelerated Conditional Approval of BiovaxID
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 14 May 2007
Accentia Biopharmaceuticals Makes Milestone Payment Based on Fast Tracked Pivotal Phase 3 Study with SinuNase for the Treatment of Chronic Sinusitis
Biopharmaceuticals
 HSMN NewsFeed - 30 Apr 2007
New Medical Device and Irrigation Solution Exhibits Promising Results in the Removal of Bacterial Colonization in Chronic Sinus and Ear Infections
Devices
 HSMN NewsFeed - 21 Dec 2006
Accentia Biopharmaceuticals in Discussions with Pharmaceutical Companies on SinuNase Partnership
Biopharmaceuticals
 HSMN NewsFeed - 6 Nov 2006
Accentia Biopharmaceuticals Commences Fast-Tracked Phase 3 Clinical Trial of SinuNase for the Treatment of Chronic Sinusitis
Biopharmaceuticals Personnel
 HSMN NewsFeed - 19 Oct 2006
New Landmark Study Shows the Use of a BiovaxID Formulation Improves Disease Free survival in 80% of Patients Whose Cancer has Relapsed after Chemotherapy Administered With or Without Rituxan
Biopharmaceuticals Oncology
 HSMN NewsFeed - 14 Jun 2006
Accentia Biopharmaceuticals Launches MD Turbo(TM) in the United States
Devices Biopharmaceuticals Drug Delivery
 HSMN NewsFeed - 24 May 2006
Association Between Molecular Remission and Disease-Free Survival in Non-Hodgkins Lymphoma at Over Nine Years Follow-Up To Be Presented
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 May 2006
FDA Gives Permission to Use Very Sensitive Molecular Evidence of Cancer in BiovaxID Pivotal Phase 3 Clinical Trial
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 11 May 2006
FDA Grants Accentia Biopharmaceuticals, Inc.'s Majority-Owned Subsidiary Fast Track Status for BiovaxID(TM)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 10 May 2006
Biovest's AutovaxID(TM) Cleared for Commercial Sale
Biopharmaceuticals Devices FDA
 HSMN NewsFeed - 8 May 2006
Accentia Biopharmaceuticals Receives FDA Approval for Three Unique Dosage Combination Pain Product ANDAs
Biopharmaceuticals FDA
 HSMN NewsFeed - 20 Apr 2006
National Survey of U.S. Otolaryngologists First to Measure Dissatisfaction with Current Treatments for Chronic Sinusitis
Biopharmaceuticals
 HSMN NewsFeed - 19 Apr 2006
Pathogenics, Inc. Licenses Worldwide Rights to Novel Anti-Infective Compound for Ophthalmological Use
Biopharmaceuticals Ophthalmology Licensing
 HSMN NewsFeed - 12 Apr 2006
FDA Grants Accentia Biopharmaceuticals Fast Track Status for SinuNase(TM)
Biopharmaceuticals FDA
 HSMN NewsFeed - 20 Mar 2006
Kurve Technology Signs Agreement With Schering-Plough Corporation
Biopharmaceuticals Drug Delivery
 HSMN NewsFeed - 22 Feb 2006
Biovest International Submits Amendment Request to FDA for Use of Molecular Remission Data in the Ongoing Pivotal Phase 3 Study to Support Accelerated, Conditional Approval of BiovaxID (TM), a Personalized Anti-Cancer Vaccine for Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 14 Feb 2006
SinuNase(TM) IND On Track
Biopharmaceuticals
Return to NewsFeed  

 Additional items found! 9

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 9 additional stories matching:
rhinosinusitis
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.